All News

The FDA grants fast track designation to VS-7375, an oral KRAS G12D dual ON/OFF inhibitor, advancing new hope for pretreated non–small cell lung cancer (NSCLC).

Suzanne Feeney, PharmD, explains why expanding clinical services—from immunizations to chronic disease management—is a critical growth strategy for independent pharmacies navigating reimbursement pressures and shifting legislation.

The agent is to be used alongside diet adjustments in adult patients.

The FDA approved palbociclib-based maintenance therapy for HR-positive, HER2-positive advanced breast cancer following a significant progression-free survival benefit in PATINA.

As these tools continue to move into mainstream diabetes management, it is increasingly important that pharmacists have proficiency.

Pharmacy Times interviews Alison Newman, MPH, Program Operations Specialist at CEDEER, about who should carry naloxone, common misconceptions surrounding overdose reversal and fentanyl-related overdoses, and the broader strategies needed to reduce overdose deaths.

Pharmacy Times interviews Alison Newman, MPH, Program Operations Specialist at CEDEER, about the FDA's expansion of over-the-counter naloxone access, remaining barriers to availability, and the critical role pharmacists play in overdose prevention and patient education.

A compliance expert breaks down the FDA's move to exclude glucagon-like peptide-1 (GLP-1) drugs from the 503B bulk's list and what it means for pharmacists and patients.

Shahida Choudhry, PharmD, discusses earning McKesson ideaShare's inaugural Trailblazer Award, building an integrated primary care and pharmacy model, and using advocacy and social media to elevate independent pharmacy.

Pharmacists should be up-to-date on current outbreak status, US risk level, and how to recognize warning signs and counsel concerned patients as confirmed Ebola cases caused by Bundibugyo ebolavirus continue to rise across the Democratic Republic of the Congo (DRC) and Uganda.

Chiadi Ndumele, MD, breaks down the cardiovascular-kidney-metabolic syndrome (CKM) guideline's glucagon-like peptide-1 (GLP-1) and kidney-protective therapy guidance—and the pharmacist's role in coordinated care.

In this interview, Chris Elder, PharmD, BCOP, discusses major themes from OPC 2026, including advances in immunotherapy delivery, practical applications of ASCO and EHA data, and the expanding role of oncology pharmacists in optimizing patient care.

The new indication is for patients aged 12 and older with unresectable or metastatic SS who received prior chemotherapy and are positive for various genetic subtypes.

In this interview, Sonia Amin Thomas, PharmD, BCOP, AFMCP, INHC, discusses common challenges in precision medicine implementation and how oncology pharmacists can build expertise in biomarker interpretation, pharmacogenomics, and multidisciplinary care.

Findings from a retrospective analysis show that montelukast prophylaxis significantly reduced rituximab infusion-related reactions, particularly among patients receiving treatment for oncology indications.

On GLP-1s like semaglutide or tirzepatide, weight loss can mean muscle loss; encourage patients to use protein and resistance training to stay strong.

Pharmacy Times speaks with Caitlin Jones, PHD, on opioids, spinal cord stimulators, and treatment-related harms in chronic low back pain.

Incorporate important health screenings and lifestyle prevention tips in MTM consults.

From AI-driven dispensing to grassroots advocacy wins, here are the key insights Pharmacy Times gathered at McKesson ideaShare 2026 in Denver.

Specialty dispensing and infusion services offer real opportunity—but the path requires careful planning, sequencing, and the right resources.

Sandie Kueker, RPh, shares how advocacy and a strong medication synchronization program have helped her independent pharmacies expand clinical services and better serve rural communities.

Emily Flaugher discusses how Health Mart Atlas tools and emerging legislative momentum are helping independent pharmacies navigate reimbursement challenges and unlock new revenue opportunities.

This OPC interview discusses emerging personalized immunotherapy approaches in melanoma, evolving toxicity management strategies, and the future role of cancer vaccines in cutaneous oncology.

Single-cell findings presented at EHA 2026 identify B cells as potential drivers of immune dysregulation in acquired hemophilia A.

Ammoxetine is a novel SNRI derived from duloxetine, exhibiting a 3- to 10-fold greater potency.

Leonard Egede explains why PHQ-9 screening belongs in every cardio-kidney-metabolic (CKM) syndrome risk assessment—and how community pharmacists can reach patients the formal system misses.

Pharmacists cut through probiotic hype by matching strains and doses to evidence, checking shelf-life potency, and navigating confusing regulations.

This abstract was presented at the Oncology Pharmacists Connect (OPC) meeting in Austin, Texas, from June 18 to 19, 2026.